Icure Pharmaceutical Incorporation
KKRX:1752501,411.00
KRW
+6.00
(+0.43%)
ISIN
KR7175250000
Return %
Stock
S&P 500
1Y
-34.98
14.39
3Y
-25.11
81.42
5Y
-89.69
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Young-Seok Lee
- Full Time Employees
- 286
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seoul South Korea
- IPO Date
- Jul 12, 2018
- Website
- icure.co.kr
- Similar Companies
- Business
- Icure Pharmaceutical Incorporation is a South Korea-based biopharmaceutical and healthcare company primarily engaged in the research, development, and manufacturing of transdermal drug delivery systems (TDDS), prescription pharmaceuticals, cosmeceuticals, and health functional foods. Founded in 2000 and headquartered in Seoul, South Korea, the company operates across two principal business divisions: Pharmaceuticals and Cosmetics. The company's core product and service portfolio comprises: transdermal patch formulations for central nervous system disorders, pain management, respiratory conditions, and dementia, including its flagship donepezil transdermal patch for Alzheimer's disease, rivastigmine patches, pramipexole patches for Parkinson's disease, fentanyl transdermal systems, tulobuterol asthma patches, ketoprofen and piroxicam anti-inflammatory plasters, and topical analgesics; contract development and manufacturing organization (CDMO) and original design manufacturing (ODM) services encompassing formulation design, clinical batch production, and commercial-scale cGMP manufacturing of transdermal patches, hydrogel plasters, cataplasms, and topical creams for third-party pharmaceutical enterprises; cosmeceutical and skincare products, including hydrogel facial mask packs, dissolvable microneedle patches, anti-aging ampoules, derma-cosmetics, and functional skincare solutions manufactured under proprietary brands such as Meditime NEO as well as on an OEM/ODM basis for global cosmetic brands; and health functional foods and dietary supplements targeting immune enhancement, joint health, and metabolic wellness. Icure Pharmaceutical distributes its products across hospital networks, retail pharmacies, dermatology clinics, and consumer health channels in South Korea, while exporting and out-licensing formulations to international markets across the Asia-Pacific region, North America, Latin America, and Europe through advanced cGMP-compliant manufacturing and R&D facilities located in Wanju and Anseong, South Korea. In recent developments, Icure Pharmaceutical has accelerated the global commercialization of its proprietary donepezil transdermal patch for Alzheimer's disease, advancing overseas regulatory filings, regional licensing, and supply agreements across Southeast Asia, Latin America, and the Middle East, while progressing clinical bridging strategies for United States market entry. The company has deepened its commercialization and distribution partnership with Celltrion for domestic and international co-marketing of transdermal dementia therapies. Additionally, Icure Pharmaceutical has expanded its pipeline into next-generation soluble microneedle delivery platforms and transdermal peptide formulations, broadened its cosmetics OEM/ODM export network, and executed strategic corporate adjustments, including capital structure optimizations, convertible instrument refinancings, and operational streamlining across manufacturing divisions to enhance profitability and support global regulatory compliance.